Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 3Melanoma 2Carcinoma, Renal Cell 2Carcinoma 2Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × ProMune × Clear all
NCT00043368 2009-03-12

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Pfizer

Phase 2 Completed
31 enrolled
BreastDermatologicGenitourinaryLymphoidThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Lymphoma, T-Cell

NCT00043407 2009-02-12

CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Pfizer

Phase 1/2 Completed
42 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡